Therapy News and Research

RSS

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar levels (glycosylated hemoglobin levels, or HbA1c) compared with placebo at 24 weeks when either agent was added to existing sitagliptin therapy (with or without metformin) in adult patients with type 2 diabetes.

11 Jun 2012

Zafgen announces new data from two Phase 1 studies of beloranib on obesity

Zafgen, Inc., the world's first biopharmaceutical company dedicated to addressing the unmet need of severely obese patients, today announced new data from two Phase 1 studies of beloranib, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed significant weight loss and improvements in cardiometabolic risk markers in severely obese women.

11 Jun 2012

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Sanofi announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus (insulin glargine [rDNA origin] injection) versus sitagliptin.

11 Jun 2012

Pre-operative aspirin therapy may reduce risk of acute kidney failure after CABG surgery

Aspirin taken for five days before a heart operation can halve the numbers of patients developing post-operative acute kidney failure, according to research presented at the European Anaesthesiology Congress in Paris.

11 Jun 2012

Cebix announces data from Ersatta Phase 1 study on type 1 diabetes

Cebix Incorporated today announced that data from a Phase 1 study demonstrated that Ersatta, the company's long-acting form of C-peptide, was well tolerated with no serious adverse events in patients with type 1 diabetes and exhibited a pharmacokinetic profile consistent with once-weekly dosing.

11 Jun 2012

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.

11 Jun 2012

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

Boehringer Ingelheim and Eli Lilly and Company presented results from a randomised Phase III clinical trial and a post-hoc analysis for linagliptin at ADA.

11 Jun 2012

BCSI launches 5 new cyclotrons for isotope research and production

Best Cyclotron Systems is unveiling five new cyclotrons for isotope research and production at the Society of Nuclear Medicine (SNM) Annual Meeting on June 9-12 in Miami Beach, Florida.

11 Jun 2012

Study confirms linear association between JBA and future stroke rate

Researchers from the Imperial College Faculty of Medicine in London in the United Kingdom revealed that the presence and size of a juxtaluminal black (hypoechoic) area (JBA) on carotid ultrasound of asymptomatic carotid artery plaques can predict the occurrence of ipsilateral ischemic stroke.

11 Jun 2012

Researchers describe germ line functions of par-5 gene

Certain proteins, such as 14-3-3, conserve their basic functions of cell cycle control in diverse organisms, from worms to humans. In a study led by Juli-n Cer-n and Sim- Schwartz Jr, researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and the Research Institute of Vall d'Hebron (VHIR) respectively, have described germ line functions of par-5, which is one of the two 14-3-3 proteins existing in Caenorhabditis elegans, worms used as experimental model in genetic studies.

10 Jun 2012

UF Proton Therapy Institute successfully treats first eye cancer patient

The fixed beam room, or eyeline, at the University of Florida Proton Therapy Institute is up and running and radiation oncologist Robert Malyapa, M.D., Ph.D. completed treating the facility's first eye cancer patient this week.

10 Jun 2012

Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage (metastatic) breast cancer.

10 Jun 2012

Promising results for dabrafenib in advanced melanoma

The BRAF inhibitor dabrafenib shows promising results for treatment of advanced melanoma, both alone and in combination with the MEK inhibitor trametinib, show results from two studies presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.

8 Jun 2012

Genetic influence on postmenopausal bone loss falls with age

The effect of genetics on bone loss rates in postmenopausal women reduces until the age of 65 years, after which time its influence disappears completely, according to results from a twin-based study.

8 Jun 2012

Rheumatoid arthritis drug has added benefits

Treatment with anti-tumor necrosis factor drugs reduces the risk for cardiovascular events in patients with rheumatoid arthritis, researchers report.

8 Jun 2012

CSL Behring rIX-FP granted Orphan Drug Designation to treat hemophilia B

CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).

8 Jun 2012

NCPA takes proactive steps against medication non-adherence

Under the leadership of its national trade association, community pharmacists are stepping up to the plate to take on the issue of medication non-adherence, a health care crisis currently adding to the nation's fiscal woes at a cost of nearly $300 billion each year.

8 Jun 2012

Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD

Amgen today announced top-line results of the Phase 3 EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated Sensipar/Mimpara (cinacalcet) for the reduction of the risk of mortality and cardiovascular (CV) events among 3,883 patients with secondary hyperparathyroidism (HPT) and chronic kidney disease (CKD) receiving dialysis.

8 Jun 2012

Smoking RA patients don't respond to anti-TNF drugs

A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, reinforces current thinking that smoking negatively affects treatment response in rheumatoid arthritis (RA) patients treated with anti-tumour necrosis factor (anti-TNF) drugs.

8 Jun 2012